Heart failure
Conditions
Interventions
case group:Nil
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Provision of informed consent prior to any study specific procedures (including run-in); 2. Female or male aged >= 18 years; 3. Diagnosed with coronary artery disease (CAD), defined as (any of the following): (1)Documented Myocardial Infarction; (2)Percutaneous Coronary Intervention; (3)Coronary Artery Bypass Grafting; (4)Objective Findings of Coronary Stenosis (>=50%) in at least 2 coronary artery territories (ie, left anterior descending, ramus intermedius, left circumflex, right coronary artery) involving the main vessel, a major branch, or a bypass graft; 4. Diagnosed with heart failure (HF), defined as (any of the following): (1)The presence of symptoms and/or signs of HF; LVEF =40%, elevated levels of NPs (BNP> 35 pg/mL and/or NT-proBNP>125 pg/mL). Diagnosed as chronic heart failure, the definition of confirmed heart failure is as follows: (1) Symptoms or signs of heart failure; (2) Increased natriuretic peptide, and conform to at least one of the following: 1) Left ventricular hypertrophy and/or left atrium enlargement; 2) Cardiac diastolic dysfunction. Note: BNP> 35 pg/mL and/or NT-proBNP>125 pg/mL.
Exclusion criteria
Exclusion criteria: 1. Acute cardiovascular event [e.g., acute coronary syndrome (ACS), transient ischemic attack (TIA), stroke, any revascularization, decompensated HF, sustained ventricular tachycardia 5µmol/L); presence of a systemic inflammatory process that might influence cerebral FDG uptake); 4. Pregnant or breast-feeding patients; 5. Active participation in another clinical study; 6. Any reason the Investigator believes the patient is not likely to be compliant with the study protocol; 7. Any conditions that, in the opinion of the Investigator, may render the patient unable to complete the study including but not limited to cardiovascular (NYHA class IV CHF, recurrent ventricular arrhythmias) or non-cardiovascular disease (e.g., active malignancy with the exception of basal cell carcinoma, cirrhosis, chronic lung disease, severe autoimmune disease) and/or a likely fatal outcome within 5 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brain natriuretic peptide;cardiac troponin I;C-reactive protein;blood glucose;Left ventricular functional parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| interleukin-6;tumor necrosis factor-a;Total cholesterol;Triglycerides;low density lipoprotein;High density lipoprotein;glycosylated hemoglobin;Insulin resistance index;t homocysteine; | — |
Countries
China
Contacts
Public ContactZhang Xiaoli
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed